Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 4 7Phase 3 7Phase 1/2 6Phase 2/3 3Phase NA 2Phase 1 2

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1Dermatomyositis 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Etanercept × Clear all
NCT00201812 2017-12-06

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
27 enrolled
Tumor-Agnostic

Neoplasms

NCT00112385 2011-06-21

A Pilot Study of Etanercept in Dermatomyositis

Brigham and Women's Hospital

Phase 1 Completed
16 enrolled 42 charts

Dermatomyositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡